Ronald A. Lubet

Q: What Schools Are Affiliated With Ronald A. Lubet

Ronald A. Lubet is affiliated with the following schools: Simon Fraser University, University of Hong Kong, MD Anderson Cancer Center, University of Minnesota, Baylor College of Medicine, University of Alabama at Birmingham

Ronald A. Lubet's AcademicInfluence.com Rankings

Ronald A. Lubet

Medical

#2698

World Rank

#3129

Historical Rank

Pharmacology

#294

World Rank

#343

Historical Rank

medical Degrees

Ronald A. Lubet

Philosophy

#7733

World Rank

#10984

Historical Rank

Logic

#4771

World Rank

#6100

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Ronald A. Lubet Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ronald A. Lubet's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. (1999) (648)
Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. (1985) (646)
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. (2000) (502)
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. (2000) (496)
Chemopreventive activity of celecoxib, a specific cyclooxygenase‐2 inhibitor, and indomethacin against ultraviolet light–induced skin carcinogenesis (1999) (426)
Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. (2000) (423)
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. (1996) (338)
Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. (1990) (330)
Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. (1996) (279)
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. (2000) (277)
Lipoxygenase inhibitors as potential cancer chemopreventives. (1999) (250)
Chemopreventive drug development: perspectives and progress. (1994) (236)
Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. (1993) (232)
Measurement of cytochrome P-450 dependent dealkylation of alkoxyphenoxazones in hepatic S9s and hepatocyte homogenates: effects of dicumarol. (1985) (229)
Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. (1997) (215)
Enhancement of experimental colon cancer by genistein. (1997) (192)
Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program (1994) (178)
Mechanistic considerations in chemopreventive drug development (1994) (165)
Progress in Cancer Chemoprevention (1999) (165)
Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. (2002) (159)
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. (2000) (157)
Risk biomarkers and current strategies for cancer chemoprevention (1996) (146)
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. (2000) (144)
Strategy and planning for chemopreventive drug development: Clinical development plans II (1994) (141)
New agents for cancer chemoprevention (1996) (131)
Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. (1994) (130)
Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. (1999) (120)
Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. (1999) (116)
Chemoprevention of Prostate Cancer: Concepts and Strategies (1999) (114)
A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. (2000) (110)
A Chemically Induced Model for Squamous Cell Carcinoma of the Lung in Mice (2004) (109)
Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. (1993) (109)
Coxibs and Other Nonsteroidal Anti-Inflammatory Drugs in Animal Models of Cancer Chemoprevention (2011) (108)
Strategy and planning for chemopreventive drug development: Clinical development plans (1996) (102)
Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. (1992) (102)
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. (1999) (100)
The effect of vitamin E acetate on ultraviolet‐induced mouse skin carcinogenesis (1998) (100)
Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity. (2010) (100)
Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. (2003) (100)
Health disparities in breast cancer: biology meets socioeconomic status (2010) (98)
Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas (2004) (97)
Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. (2001) (96)
Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis (2004) (96)
A pleiotropic response to phenobarbital-type enzyme inducers in the F344/NCr rat. Effects of chemicals of varied structure. (1992) (94)
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. (2003) (90)
Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. (1999) (89)
Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. (1996) (87)
Chemoprevention in hereditary colorectal cancer syndromes (1999) (85)
Modulation of biomarkers by chemopreventive agents in smoke-exposed rats. (2001) (84)
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. (1999) (83)
Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. (1999) (82)
Aromatase inhibitors as potential cancer chemopreventives. (1998) (81)
Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. (1998) (79)
Induction of hepatic cytochrome P-450 mediated alkoxyresorufin O-dealkylase activities in different species by prototype P-450 inducers. (1990) (78)
Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine‐induced urinary bladder cancers (2008) (76)
Progress in clinical chemoprevention. (1997) (76)
Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients (2012) (75)
Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. (2003) (75)
Induction of alkoxyresorufin O-dealkylases, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates. (1987) (73)
Comparative pharmacodynamics of CYP2B induction by DDT, DDE, and DDD in male rat liver and cultured rat hepatocytes. (1998) (72)
Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. (2010) (71)
Alterations of gene expression in skin and lung of mice exposed to light and cigarette smoke (2004) (70)
Formation and persistence of nucleotide alterations in rats exposed whole-body to environmental cigarette smoke. (1999) (69)
Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. (1995) (69)
Induction of Cytochrome P450b and Its Relationship to Liver Tumor Promotion (1989) (69)
Chemopreventive efficacy of anethole trithione, N‐acetyl‐L‐cysteine, miconazole and phenethylisothiocyanate in the DMBA‐induced rat mammary cancer model (1997) (68)
Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. (2001) (68)
Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis. (2003) (68)
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer (2005) (67)
Genetic alterations in mouse lung tumors: Implications for cancer chemoprevention (1997) (67)
Cytosol-mediated reduction of resorufin: a method for measuring quinone oxidoreductase. (1984) (67)
Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. (1997) (66)
Enhancement of hepatocarcinogenesis and induction of specific cytochrome P450-dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl- and 5-ethylbarbituric acids. (1994) (66)
Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. (2003) (66)
Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. (2002) (65)
Taxifolin Suppresses UV-Induced Skin Carcinogenesis by Targeting EGFR and PI3K (2012) (65)
5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. (1999) (64)
Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. (2006) (64)
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. (1994) (64)
Oxidative metabolism of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine) by rat liver microsomes. (1979) (62)
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. (2001) (62)
Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models (2004) (62)
Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. (1999) (62)
A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease (2013) (60)
Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. (2002) (59)
P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. (1988) (59)
Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. (1994) (59)
K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. (1995) (58)
Strategies for identification and clinical evaluation of promising chemopreventive agents. (1996) (58)
Chemoprevention of genome, transcriptome, and proteome alterations induced by cigarette smoke in rat lung. (2005) (57)
The induction of alkoxyresorufin metabolism: A potential indicator of environmental contamination (1990) (57)
5‐aminosalicylic acid inhibits colitis‐associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium‐induced colitis (2008) (56)
The use of animal models for cancer chemoprevention drug development. (2010) (55)
Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K (2013) (55)
Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. (2002) (54)
Differentially expressed genes associated with mouse lung tumor progression (2002) (54)
Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. (1996) (53)
Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. (2006) (53)
Chemoprevention of Rat Prostate Carcinogenesis by Soy Isoflavones and by Bowman-Birk Inhibitor (2007) (53)
Null Activity of Selenium and Vitamin E as Cancer Chemopreventive Agents in the Rat Prostate (2010) (52)
Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. (1999) (52)
Pilot studies evaluating the lung tumor yield in cigarette smoke-exposed mice. (2001) (52)
Lung Cancer Inhibitory Effect of Epigallocatechin-3-Gallate Is Dependent on Its Presence in a Complex Mixture (Polyphenon E) (2009) (51)
Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions (2004) (50)
Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. (2000) (50)
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. (2004) (49)
Chemopreventive effect of perillyl alcohol on 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung (1997) (49)
Short-term Modulation of Cell Proliferation and Apoptosis and Preventive/Therapeutic Efficacy of Various Agents in a Mammary Cancer Model (2007) (48)
Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. (1998) (47)
Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. (2002) (47)
Chemopreventive Efficacy of Naproxen and Nitric Oxide–naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers (2009) (47)
Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. (2005) (47)
Tumor-promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine. (1992) (47)
Induction of alopecia in mice exposed to cigarette smoke. (2000) (47)
Beetroot red (betanin) inhibits vinyl carbamate‐ and benzo(a)pyrene‐induced lung tumorigenesis through apoptosis (2013) (46)
SAGE profiling of UV‐induced mouse skin squamous cell carcinomas, comparison with acute UV irradiation effects (2005) (46)
Modulation of multigene expression and proteome profiles by chemopreventive agents. (2005) (45)
Clinical development plan: N-(4-hydroxyphenyl)retinamide. (1994) (45)
Lung DNA adducts detected in human smokers are unrelated to typical polyaromatic carcinogens. (2006) (45)
CHEMOPREVENTION OF VINYL CARBAMATE-INDUCED LUNG TUMORS IN STRAIN A MICE (2000) (45)
Tumorigenesis in the multiple intestinal neoplasia mouse (2000) (45)
Chemoprevention of Lung Squamous Cell Carcinoma in Mice by a Mixture of Chinese Herbs (2009) (44)
Mechanistic considerations in the evaluation of chemopreventive data. (1996) (44)
An interlaboratory comparison of transformation in Syrian hamster embryo cells with model and coded chemicals. (1986) (44)
Gene Expression in the Lung of p53 Mutant Mice Exposed to Cigarette Smoke (2004) (44)
Chemopreventive Effects of Pioglitazone on Chemically Induced Lung Carcinogenesis in Mice (2010) (43)
Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. (2003) (43)
Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. (1996) (43)
Potential use of lipoxygenase inhibitors for cancer chemoprevention (2000) (43)
Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. (2004) (42)
USE OF p53 TRANSGENIC MICE IN THE DEVELOPMENT OF CANCER MODELS FOR MULTIPLE PURPOSES (2000) (41)
Prediction of Molecular Targets of Cancer Preventing Flavonoid Compounds Using Computational Methods (2012) (41)
Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. (1998) (41)
Farnesyl protein transferase inhibitors as potential cancer chemopreventives. (1997) (40)
Induction of cytochrome P450 and other drug metabolizing enzymes in rat liver following dietary exposure to Aroclor 1254. (1991) (40)
Systemic genotoxic effects produced by light, and synergism with cigarette smoke in the respiratory tract of hairless mice. (2003) (40)
Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1 (2013) (40)
Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice (2011) (40)
Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. (2004) (40)
Gene expression profiling of chemically induced rat bladder tumors. (2007) (38)
Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf (2005) (38)
Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. (2010) (38)
Quercetin‐3‐methyl ether inhibits lapatinib‐sensitive and ‐resistant breast cancer cell growth by inducing G2/M arrest and apoptosis (2013) (38)
An interlaboratory evaluation of the Syrian hamster embryo cell transformation assay using eighteen coded chemicals. (1988) (38)
Overexpression of Cyclooxygenase-2 in Rat Oral Cancers and Prevention of Oral Carcinogenesis in Rats by Selective and Nonselective COX Inhibitors (2010) (38)
6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1. (2014) (37)
Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. (2005) (37)
Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis (2009) (37)
Prevention of lung cancer progression by bexarotene in mouse models (2006) (37)
Effect of 3-aminobenzamide on the induction of toxicity and transformation by ethyl methanesulfonate and methylcholanthrene in BALB/3T3 cells. (1984) (36)
Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf (2003) (36)
Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism (2005) (36)
Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols (2007) (36)
Therapy of the murine plasmacytoma MOPC 104E: role of the immune response. (1978) (36)
Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. (1994) (36)
A gene expression signature that can predict green tea exposure and chemopreventive efficacy of lung cancer in mice. (2006) (35)
In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. (1997) (34)
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy. (2010) (34)
Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer (2006) (34)
Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function (2014) (34)
Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. (2001) (34)
Biological effects of the Sudan dyes. Role of the Ah cytosolic receptor. (1983) (33)
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. (2005) (33)
Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine. (2004) (33)
Aerosolized 3-Bromopyruvate Inhibits Lung Tumorigenesis without Causing Liver Toxicity (2012) (33)
p53 Transgenic Mice Are Highly Susceptible to 4-Nitroquinoline-1-Oxide-Induced Oral Cancer (2006) (32)
The effect of PPARγ ligands on UV‐ or chemically‐induced carcinogenesis in mouse skin (2005) (32)
Quantitative Monitoring of Adenocarcinoma Development in Rodents by Magnetic Resonance Imaging (2008) (31)
The Chemopreventive Efficacies of Nonsteroidal Anti-inflammatory Drugs: The Relationship of Short-term Biomarkers to Long-term Skin Tumor Outcome (2013) (30)
4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. (2004) (30)
Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours. (2003) (30)
Cell Proliferation, Apoptosis, and Expression of Cyclin D1 and Cyclin E as Potential Biomarkers in Tamoxifen-Treated Mammary Tumors (2003) (30)
S-allylcysteine, a garlic constituent, fails to inhibit N-methylnitrosourea-induced rat mammary tumorigenesis. (1999) (30)
9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats. (2002) (29)
Chemical enhancement of SA7 virus transformation of hamster embryo cells: evaluation by interlaboratory testing of diverse chemicals. (1986) (29)
Effect of budesonide on the methylation and mRNA expression of the insulin‐like growth factor 2 and c‐myc genes in mouse lung tumors (2002) (28)
Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. (1992) (28)
Prevention of mouse lung tumors by targretin (2006) (28)
CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors (2004) (28)
Identification of novel transcriptional networks in response to treatment with the anticarcinogen 3H-1,2-dithiole-3-thione. (2006) (28)
Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver. (1996) (28)
Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death. (2000) (27)
Induction of hepatic CYP1A activity as a biomarker for environmental exposure to Aroclor® 1254 in feral rodents (1992) (27)
Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors. (1998) (27)
Relationship between DNA strand breaks and inhibition of poly (ADP-ribosylation): enhancement of carcinogen-induced transformation. (1986) (27)
Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. (1999) (27)
Preventive Effects of Bexarotene and Budesonide in a Genetically Engineered Mouse Model of Small Cell Lung Cancer (2009) (27)
Strategies for phase II cancer chemoprevention trials: Cervix, endometrium, and ovary (1995) (27)
CHEMOPREVENTIVE EFFICACY OF PROMISING FARNESYLTRANSFERASE INHIBITORS (2000) (27)
Preclinical drug development paradigms for chemopreventives. (1998) (27)
Lack of Effect of Metformin on Mammary Carcinogenesis in Nondiabetic Rat and Mouse Models (2015) (26)
Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. (2013) (26)
The chemopreventive agent diallyl sulfide. A structurally atypical phenobarbital-type inducer. (1995) (26)
Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. (1999) (26)
Effect of calcium on azoxymethane-induced aberrant crypt foci and cell proliferation in the colon of rats. (1998) (26)
Effects on Gene Expression in Rat Liver after Administration of RXR Agonists: UAB30, 4-Methyl-UAB30, and Targretin (Bexarotene) (2013) (25)
A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice (2006) (25)
Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors (2006) (25)
Induction of mutagenesis and transformation in BALB/c‐3T3 clone A31‐1 cells by diverse chemical carcinogens (1990) (25)
The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. (2005) (25)
Relative potencies of induction of hepatic drug-metabolizing enzyme genes by individual PCB congeners. (1995) (25)
Discovery of Novel Checkpoint Kinase 1 Inhibitors by Virtual Screening Based on Multiple Crystal Structures (2011) (25)
Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. (1999) (25)
Effect of Dietary Polyphenon E and EGCG on Lung Tumorigenesis in A/J Mice (2010) (24)
Inhibition of cigarette smoke-related DNA adducts in rat tissues by indole-3-carbinol. (2000) (24)
Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: Chemoprevention by budesonide and N-acetylcysteine (2006) (24)
Development of breast cancer chemopreventive drugs (1993) (24)
Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C? (2011) (24)
(3-Chloroacetyl)-indole, a Novel Allosteric AKT Inhibitor, Suppresses Colon Cancer Growth In Vitro and In Vivo (2011) (24)
Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis. (2000) (24)
Induction of a pleiotropic response by phenobarbital and related compounds. Response in various inbred strains of rats, response in various species and the induction of aldehyde dehydrogenase in Copenhagen rats. (1992) (24)
Lung cancer chemoprevention: difficulties, promise and potential agents? (2013) (24)
Interlaboratory evaluation of the C3H/10T1/2 cell transformation assay. (1988) (23)
Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. (2017) (23)
Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator (2019) (23)
Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer (2004) (23)
Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide (2006) (23)
Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor (2001) (23)
The metabolic activation of benzo(a)pyrene and 9‐hydroxybenzo (a) pyrene by liver microsomal fractions (1979) (23)
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes (2008) (22)
Chemopreventive effect of a mixture of Chinese Herbs (antitumor B) on chemically induced oral carcinogenesis (2013) (22)
Subchronic dietary exposure to Aroclor 1254 in rats: accumulation of PCBs in liver, blood, and adipose tissue and its relationship to induction of various hepatic drug-metabolizing enzymes. (1994) (22)
Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and alpha-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. (1996) (22)
Pre-Clinical Applications of Transgenic Mouse Mammary Cancer Models (2002) (22)
Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs (2005) (22)
Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. (2000) (21)
Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. (2009) (21)
Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. (2006) (21)
p53 transgenic mice are highly susceptible to 1, 2-dimethylhydrazine-induced uterine sarcomas. (2002) (21)
K-ras MUTATIONS IN LUNG TUMORS FROM p53 MUTANT MICE EXPOSED TO CIGARETTE SMOKE (2005) (20)
Cytochrome P450 induction in feral Cricetid rodents: a review of field and laboratory investigations. (1998) (20)
Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model (2013) (20)
Animal models of lung cancer characterization and use for chemoprevention research. (2012) (20)
Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozole (2000) (20)
Mouse Models Incorporating Alterations In The Major Tumor Suppressor Genes P53 And P16: Their Use In Screening For Potential Carcinogens, Developing Further Relevant Mouse Models, And Screening For Potential Chemopreventive And Chemotherapetutic Agents (2004) (20)
Aerosolized Bexarotene Inhibits Lung Tumorigenesis without Increasing Plasma Triglyceride and Cholesterol Levels in Mice (2010) (20)
Dose-response relationships for the induction of P450 2B by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in rat and cultured rat hepatocytes (1993) (20)
Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer (2017) (20)
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents (2016) (19)
Induction of Invasive Mouse Skin Carcinomas in Transgenic Mice with Mutations in Both H-ras and p53 (2005) (19)
Absence of hepatic microsomal pentyl- or benzyl-resorufin O-dealkylase induction in rainbow trout (Salmo gairdneri) treated with phenobarbitone. (1987) (19)
Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer (2016) (19)
Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations (2006) (19)
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT). (2007) (18)
Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo (2013) (18)
Differential gene expression in chemically induced mouse lung adenomas. (2003) (18)
Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model. (1999) (18)
Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine (2017) (18)
Targeting the insulin‐like growth factor‐1 receptor by picropodophyllin for lung cancer chemoprevention (2015) (18)
Comparative pharmacodynamics of CYP2B induction by phenobarbital in the male and female F344/NCr rat. (1993) (17)
Novel mutational landscapes and expression signatures of lung squamous cell carcinoma (2017) (17)
Null Effect of Dietary Restriction on Prostate Carcinogenesis in the Wistar-Unilever Rat (2007) (17)
Modulation of Gene Expression and Cell-Cycle Signaling Pathways by the EGFR Inhibitor Gefitinib (Iressa) in Rat Urinary Bladder Cancer (2011) (17)
Enhanced Antitumor Activity of 3-Bromopyruvate in Combination with Rapamycin In Vivo and In Vitro (2015) (17)
Comparative pharmacodynamics of hepatic cytochrome P450 2B induction by 5,5-diphenyl- and 5,5-diethyl-substituted barbiturates and hydantoins in the male F344/NCr rat. (1994) (16)
Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy (2015) (16)
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT). (2007) (16)
Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo (2012) (16)
Induction of hepatic CYP1A in male F344/NCr rats by dietary exposure to Aroclor 1254: examination of immunochemical, RNA, catalytic, and pharmacokinetic endpoints. (1992) (16)
A method for the amplification of chemically induced transformation in C3H/10T1/2 clone 8 cells: its use as a potential screening assay. (1987) (16)
Detection of differentially expressed genes in mouse lung adenocarcinomas. (2001) (16)
Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis. (2000) (15)
Evaluation of cell proliferation in the kidneys of rodents with bromodeoxyuridine immunohistochemistry of tritiated thymidine autoradiography after exposure to renal toxins, tumor promoters, and carcinogens. (1991) (15)
Lapatinib, a Preventive/Therapeutic Agent against Mammary Cancer, Suppresses RTK-Mediated Signaling through Multiple Signaling Pathways (2011) (15)
Transcriptomic analysis by RNA‐seq reveals AP‐1 pathway as key regulator that green tea may rely on to inhibit lung tumorigenesis (2014) (15)
Preferential Decrease in Thymus Dependent Lymphocytes during Storage at 4 C in Anticoagulant (1976) (15)
The role of 3-OH benzo(a)pyrene in mediating benzo(a)pyrene induced toxicity and transformation in cell culture. (1973) (15)
Chemoprevention of lung cancer in transgenic mice. (2004) (15)
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ (2015) (15)
Clinical Development Plan (2020) (15)
Inhibition of cigarette smoke-related lipophilic DNA adducts in rat tissues by dietary oltipraz. (1998) (14)
Tumor promoting activities of ethylphenylacetylurea and diethylacetylurea, the ring hydrolysis products of barbiturate tumor promoters phenobarbital and barbital, in rat liver and kidney initiated by N-nitrosodiethylamine. (1989) (14)
A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumors (1999) (14)
Development of Breast Cancer Chemopreventive Drugs (1995) (14)
Preferential activation of 6-aminochrysene and 2-aminoanthracene to mutagenic moieties by different forms of cytochrome P450 in hepatic 9000 X g supernatants from the rat. (1989) (14)
Tissue-specific expression of the K-ras allele from the A/J parent in (A/J x TSG-p53) F1 mice. (1997) (14)
Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues. (1997) (14)
Clinical development plan: N-Acetyl-l-cysteine. (1994) (14)
Effects of 3-aminobenzamide on the induction of morphologic transformation by diverse compounds in Balb/3T3 cells in vitro. (1986) (14)
Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea (2001) (14)
Clinical development plan: 2‐Difluoromethylornithine (DFMO) (1994) (13)
Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat (2000) (13)
Multiple comparisons model-based clustering and ternary pattern tree numerical display of gene response to treatment: procedure and application to the preclinical evaluation of chemopreventive agents. (2002) (13)
Hereditary cancer syndromes as model systems for chemopreventive agent development. (2016) (13)
Induction of cytochrome P-450 in Sigmodon hispidus (cotton rats) exposed to dietary Aroclor 1254. (1994) (13)
Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets. (2006) (13)
Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element. (2009) (13)
Advances in Brief The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Preventive and Therapeutic Agent in the Min Mouse Model of Adenomatous Polyposis 1 (2000) (13)
Cytosol-mediated reduction of resorufin fluorescence: effects on the ethoxyresorufin O-deethylase (ETR) assay. (1983) (13)
Clinical development plan: Vitamin E (1994) (13)
Src is a novel potential off‐target of RXR agonists, 9‐cis‐UAB30 and Targretin, in human breast cancer cells (2015) (12)
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. (2006) (12)
CHEMOPREVENTION: MOUSE COLON AND LUNG TUMOR BIOASSAY AND MODULATION OF DNA METHYLATION AS A BIOMARKER (2005) (12)
Absence of enantioselectivity in the pharmacodynamics of P450 2B induction by 5-ethyl-5-phenylhydantoin in the male rat liver or in cultured rat hepatocytes. (1994) (12)
Hepatic cytochrome P450 2B-type induction by ethyl/phenyl-substituted congeners of phenobarbital in the rat. (1993) (12)
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model (2008) (12)
Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis (2013) (12)
Enhanced Susceptibility to Chemical Induction of Ovarian Tumors in Mice with a Germ Line p53 Mutation (2008) (11)
Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes. (1993) (11)
Induction of neoplastic transformation and DNA single-strand breaks in C3H/10T1/2 clone 8 cells by polycyclic hydrocarbons and alkylating agents. (1983) (11)
Modulation by budesonide of a CpG endonuclease in mouse lung tumors. (2007) (11)
Accumulation and persistence of individual polychlorinated biphenyl congeners in liver, blood, and adipose tissue of rats following dietary exposure to Aroclor® 1254 (1994) (11)
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. (2004) (11)
Dibenz[a,h]anthracene-induced subcutaneous tumors in mice. Strain sensitivity and the role of carcinogen metabolism. (1983) (11)
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers. (2011) (10)
Lack of promoting effect of clonazepam on the development of N-nitrosodiethylamine-initiated hepatocellular tumors in mice is correlated with its inability to inhibit cell-to-cell communication in mouse hepatocytes. (1989) (10)
Can animal models help us select specific compounds for cancer prevention trials? (2005) (10)
Modulation by bexarotene of mRNA expression of genes in mouse lung tumors (2008) (10)
Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes (2013) (10)
Effects of sublethal gamma radiation on T and B cell activity in the antibody response of mice. (1976) (10)
Quantitation of aryl hydrocarbon hydroxylase activity in individual fetal hamster cells in vitro. (1972) (10)
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin (2012) (10)
Tumor immunity directed against MOPC 104E: Effect of various therapeutic regimens (1977) (9)
Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma (2019) (9)
Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention. (2004) (9)
Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. (1994) (9)
Effect of dietary Aroclor 1254 exposure on lung and kidney cytochromes P450 in female rats: evidence for P4501A2 expression in kidney. (1995) (9)
A markedly diminished pleiotropic response to phenobarbital and structurally-related xenobiotics in Zucker rats in comparison with F344/NCr or DA rats. (1992) (9)
Hypermethylation patterns in the Fhit regulatory region are tissue specific (2005) (9)
Morphological transformation of BALB/3T3 cells by various procarcinogens in the presence of a rat liver S‐9 activation system (1990) (9)
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. (2012) (9)
Phenobarbital and related compounds: approaches to interspecies extrapolation. (1992) (8)
Analysis of the interlaboratory and intralaboratory reproducibility of the enhancement of simian adenovirus SA7 transformation of Syrian hamster embryo cells by model carcinogenic and noncarcinogenic compounds. (1986) (8)
Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats. (2007) (8)
Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. (2001) (8)
Liver tumor promoters and other mouse liver carcinogens. (1990) (8)
Chemoprevention of mammary carcinogenesis in a transgenic mouse model by α-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity (2003) (8)
Clinical development plan: Sulindac (1994) (7)
Detection of differentially expressed genes in Methylnitrosourea‐induced rat mammary adenocarcinomas (1997) (7)
Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice. (2019) (7)
Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis (1996) (7)
Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention (2021) (7)
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers (2019) (7)
Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA (2021) (7)
Mouse models of triple negative [basal-like/claudin low] breast cancer. (2010) (7)
Further thoughts on preclinical animal models for cancer prevention: when is it best to start treatment? What are potential histopathologic endpoints? (2010) (7)
Induction of immunotoxicity in mice by polyhalogenated biphenyls (1986) (6)
Aryl Hydrocarbon Hydroxylase Activity “Of Mice and Humans” (1983) (6)
Association between susceptibility to dibenzanthracene‐induced fibrosarcoma formation and the Ah locus (1983) (6)
Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma (2019) (6)
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (2018) (6)
Correlation of inhibition of colitis-associated dysplasia by celecoxib with degree of inflammation in the mouse model of DSS-induced colitis. (2004) (6)
Global molecular changes in rat livers treated with RXR agonists: a comparison using transcriptomics and proteomics (2014) (6)
Transforming growth factors-β are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system (2000) (6)
Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity. (1978) (6)
COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of Type I tumor infiltrating lymphocytes. (2022) (5)
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma (2018) (5)
NSAIDs and Coxibs in Chemoprevention Non-steroidal Anti-inflammatory Drugs and Coxibs In Chemoprevention : A Commentary Based Primarily on Animal Studies (2011) (5)
Clinical development plan: 18beta-glycyrrhetinic acid. (1994) (5)
Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents (2018) (5)
Effects of celecoxib, polyphenon E and rosiglitazone on hydroxybutyl(butyl)-nitrosamine (OH-BBN) –induced urinary bladder cancers in female Fischer-344 rats. (2004) (5)
Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression (2018) (5)
5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target? (2016) (5)
Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer (2017) (5)
Dose-response relationships for cytochrome P450 induction by phenobarbital in the cotton rat (Sigmodon hispidus). (1998) (5)
Perspectives on chemoprevention agent selection and short-term clinical prevention trials. (1996) (4)
Effects of Dehydroepiandrosterone on MNU‐Induced Breast Cancer in Sprague‐Dawley Rats (1995) (4)
Effects of the oxazolidinedione anticonvulsants trimethadione and dimethadione and the barbiturate homolog 5,5-dimethylbarbituric acid onN-nitrosodiethylamine-initiated renal and hepatic carcinogenesis in the F344/NCr rat (2005) (4)
Pharmacometabolomic Pathway Response of Effective Anticancer Agents on Different Diets in Rats with Induced Mammary Tumors (2019) (4)
Hepatic cytochrome P450 2B induction by ethyl/phenyl-substituted congeners of phenobarbital in the B6C3F1 mouse. (1994) (4)
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT). (2007) (4)
Clinical development plan: beta-carotene and other carotenoids. (1994) (4)
Chemical enhancement of SA7 virus transformation of hamster embryo cells: interlaboratory testing of diverse chemicals. (1985) (4)
Clinical development plan: Tamoxifen (1994) (4)
Tumor immunity against MOPC 104E: leukocyte adherence inhibition (L.A.I.) assay. (1980) (4)
Chemoprevention of DMBA-induced Mammary Carcinogenesis: Relationship Between Induction of Phase II Enzymes, Effects on DMBA-induced Hemoglobin Adducts and Decreases in Mammary Tumor Multiplicity (2000) (4)
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer (2022) (4)
Clinical development plan: Oltipraz (1994) (4)
Clinical development plan: Aspirin (1994) (4)
Effect of early vs. late administration of 4‐Hydroxyphenylretinamide (4‐HPR) on N‐Methyl‐N‐Nitrosourea (MNU)‐induced mammary tumorigenesis (1997) (4)
Influence of various parameters on benzo(a)pyrene enhancement of adenovirus SA7 transformation of Syrian hamster embryo cells. (1986) (4)
Abstract 2820: Omeprazole alone, or in combination with Aspirin inhibits azoxymethane-induced colon adenoma progression to adenocarcinoma and carcinoma invasion in F344 rat model (2015) (3)
In Vitro Cellular Uptake of Benzo [a] pyrene Measured by a Microfluorometric Technique 1 (1971) (3)
Effects of the nonspecific COX1 and COX2 inhibitor piroxicam and the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) on development of intestinal tumors in mice bearing germline alterations in the MSH2 or APC genes (2001) (3)
Clinical development plan: Piroxicam (1994) (3)
Predictive Value Tools as an Aid in Chemopreventive Agent Development. (2013) (3)
The relationship of cellular metabolism of benzo(a)pyrene to the ind-uction of cytotoxicity and cell transformation in fetal hamster cells in vitro. (1975) (3)
Effects of 3-Aminobenzamide on the Induction of Toxicity and Transformation by Various Chemicals in BALB/3T3 Cl A 31–1 Cells (1985) (3)
Lack of chemopreventive activity of lycopene in the Wistar-Unilever rat prostate cancer model (2004) (3)
A method for amplification of sensitivity of the c3h 10t1/2 cell transformation assay. Abstr. (1982) (3)
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (2018) (3)
Perspectives and progress in development of breast cancer chemopreventive drugs. (1997) (3)
Abstract 4983: Intermittent dosing regimens of naproxen and aspirin inhibit azoxymethane-induced rat colon adenoma progression to adenocarcinoma and carcinoma invasion (2018) (3)
Select Dietary Phytochemicals Function as Inhibitors of COX-1 but Not COX-2 (2013) (3)
Effects of High-Fructose Diet vs. Teklad Diet in the MNU-Induced Rat Mammary Cancer Model: Altered Tumorigenesis, Metabolomics and Tumor RNA Expression (2021) (3)
Clinical development plan: Proscar. (1994) (3)
Identification of new agents for the prevention of prostate cancer using preclinical animal models (2003) (2)
Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995. (1995) (2)
Induction of Hepatic Cytochromes P450 by Dietary 1,4-Bis[2–(3,5–dichloropyridyloxy)] benzene (TCPOBOP) in the B6C3F1 Mouse: Dose-Dependence and Pharmacodynamics (1999) (2)
DNA Strand Breaks and Poly(ADP-Ribosylated) Mediation of Transcriptionally Active Chromatin and Transforming Gene Stability (1985) (2)
Metabolic activation of benzo[a]pyrene and 9-hydorxybenzo[a]pyrene by tissue fractions from rat liver and lung [proceedings]. (1979) (2)
Rationale for the selection and use of in vitro assays to screen for chemopreventive agents (1997) (2)
Enhanced Lung Tumor Development in Tobacco Smoke-Exposed p53 Transgenic and Kras2 Heterozygous Deficient Mice (2007) (2)
Clinical development plan: Ibuprofen (1994) (2)
4-HYDROXYBUTYL(BUTYL)NITROSAMINE (OH-BBN)- INDUCED URINARY BLADDER CANCERS IN MICE: CHARACTERIZATION OF FHIT, SURVIVIN AND COX-2 EXPRESSION AND CHEMOPREVENTIVE EFFECTS OF INDOMETHACIN (2004) (2)
P3-10-01: Alternative Dosing Regimens with the EGFr Inhibitors (Gefitinib and Lapatinib) in Mammary Cancer Models: Prevention and Therapeutic Efficacy. (2011) (2)
Symposium : Diet , Natural Products and Cancer Prevention : Progress and Promise Progress in Cancer Chemoprevention : Development of Diet-Derived Chemopreventive Agents 1 (2000) (2)
Effects of budesonide on overall 5-methylcytosine levels and specific methylation and messenger RNA expression of the insulin-like growth factor II gene in mouse lung tumors. (2004) (2)
Clinical development plan: Calcium (1994) (2)
Dose-response relationships for the induction of P450 2B by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzne (TCPOBOP) in rat and cultured rat hepatocytes. (1993) (2)
Abstract B110: Chemoprevention of rat oral carcinogenesis by licofelone, a dual cyclooxygenase/lipoxygenase inhibitor (2012) (1)
Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients (2012) (1)
Pioglitazone-mediated reversal of elevated glucose metabolism in the airway epithelium of mouse lung adenocarcinomas. (2017) (1)
Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat (44493) (2000) (1)
Effect of high retinoid doses on RAR-beta mRNA expression in female B6D2F1 mice. (2001) (1)
Abstract 2273: Metformin promotes tumorigenesis in animal models of cancer prevention. (2013) (1)
Preventive effects of the EGFR inhibitor Iressa on chemically-induced urinary bladder cancers: Histopathological and biochemical endpoints (2007) (1)
Abstract 4573: 6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1 (2015) (1)
Clinical development plan: Vitamin D3 and analogs (1994) (1)
Potential Use of Transgenic Mice in Chemoprevention Studies (2005) (1)
Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing, Combining EGFR Inhibitors with Naproxen, and Effects on RNA Expression (2021) (1)
Prostatitis and Urethritis (1999) (1)
Proton Pump Inhibitor Omeprazole Suppresses Carcinogen-induced Colonic Adenoma Progression to Adenocarcinoma in F344 Rat (2021) (1)
Abstract 4989: Efficacy of erlotinib and/or naproxen when administered by intermittent dosing schedules in the prevention of chemically induced urinary bladder cancers (2018) (1)
Abstract 1039: CREB (Ser133) phosphorylation is abnormally increased in tumors showing resistance to Iressa treatment (2011) (1)
Abstract 1858: Inhibition of oral carcinogenesis in rats by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA) (2011) (1)
Induction of phase II drug metabolizing enzymes in rat liver by various agents: Is there a coordinate response? (2007) (1)
EnhancedAntitumorActivity of 3-Bromopyruvate in Combination with Rapamycin In Vivo and In Vitro (2015) (1)
Molecular reclinical Development Cancer herapeutics hemopreventive Effects of Pioglitazone on Chemically T e duced Lung Carcinogenesis in (2010) (1)
Characterization of dose-response relationships in the induction of liver drug metabolizing enzymes in F344 rats by graded doses of Aroclor 1254 (1990) (1)
p 53 Transgenic Mice Are Highly Susceptible to 1 , 2-Dimethylhydrazine-induced Uterine Sarcomas 1 (2002) (1)
The use of drug metabolizing enzymes as a marker of exposure to low doses of polychlorinated biphenyls pcbs in rodents laboratory and field studies (1991) (1)
Advances in Brief Chemoprevention of Rat Prostate Carcinogenesis by 9-cis-Retinoic Acid 1 (1999) (1)
Abstract 5260: NGS Transcriptome analysis of colon adenocarcinomas treated with individual and combination of aspirin and omeprazole (2017) (1)
Feeding thiol-containing compounds, derived from vegetables, fails to inhibit N-methylnitrosourea-induced mammary tumorigenesis. (2001) (1)
THE METABOLISM OF 3- AND 9-HYDROXYBENZO(a)PYRENE BY RAT LIVER MICROSOMAL FRACTIONS (1980) (1)
Abstract 5402: Synergism of Metformin and DFMO on colon cancer proliferation and migration. (2013) (1)
Abstract 5255: Comparison of high-fructose and standard diets in methylnitrosourea (MNU)-induced ER+mammary cancers: Altered carcinogenesis, differential effects of metformin, and metabolomic differences (2017) (0)
P5-06-11: Quercetin-3-Methyl Ether Inhibits Lapatinib-Sensitive and Lapatinib-Resistant Breast Cancer Cell Growth by Inducing G2/M Arrest and Apoptosis. (2011) (0)
Induction of morphological transformation of c3h 10t1/2 clone 8 cells in the presence of exogenous metabolic activation. Abstr. (1980) (0)
Abstract 5564: Lack of efficacy of metformin in several standard prevention models: Methylnitrosourea rat mammary (ER+), MMTV-Neu/p53 mouse mammary (ER−) and the Min mouse colon (2011) (0)
Chemoprevention in hereditary colorectal cancer syndromes (1999) (0)
Tumorigenesis in the mult mouse: Redundancy of ne! (2016) (0)
Abstract 1244: RXR agonist induced changes in gene expression in liver and mammary cancers: Confirmation by RT-PCR on independent samples collected years apart (2010) (0)
Abstract 1849: Chemopreventive efficacy of naproxen, sulindac, and their nitric oxide-derivatives in the hydroxylbutyl(butyl)nitrosamine induced model of urinary bladder cancer (2011) (0)
Abstract 2413: Preventing the development of breast cancer by immunizing with multi-antigen vaccines targeting breast cancer proteins (2010) (0)
Inhibition of colitis-associated dysplasia by celecoxib in the mouse model of DSS-induced colitis* (2003) (0)
SHORT REPORT Prevention of mouse lung tumors by targretin (2006) (0)
Multi-modality imaging of N-methyl-N-nitrosourea-induced mammary tumors by MRI and small animal PET. (2009) (0)
Effects of methyl derivatives of the rexinoid UAB30 on methylnitrosourea (MNU) induced mammary cancers and on various indicators of toxicity. (2009) (0)
Abstract LB-457: Effect of naproxen and NO-naproxen on intestinal neoplasia in the Apc +/Min-FCCC mouse model (2011) (0)
DMBA treatment of heterozygous MMTV-Neu and MMTV-Neu/P53 knockout mice: histopathologic characterization, array analysis, and chemopreventive efficacy of rexinoids. (2007) (0)
Abstract B49: Use of MMTV-Neu/P53 KO transgenic mice to screen for potential chemopreventive agents (2010) (0)
Abstract A94: Preventive effects of naproxen and NO‐naproxen in carcinogen induced models of urinary bladder, colon, and mammary cancers (2009) (0)
Abstract A80: Modified dosing schedules with the EGFr inhibitors gefitinib and lapatinib in rodent models of mammary and urinary bladder cancer: Preventive and therapeutic effects. (2011) (0)
Development Cancer herapeutics hemopreventive Effects of Pioglitazone on Chemically T e duced Lung Carcinogenesis in Mic (2010) (0)
Abstract 1266: Downregulation of PD-L1 by NSAID administration augments the effects of a multi-antigen vaccine for the prevention of adenomatous polyps in APC(Min/+) mice (2018) (0)
Induction of neoplastic transformation and single strand dna breaks in c3h 10t1/2 cells by polycyclic hydrocarbon and short chain alkylating agents. Abstr. (1982) (0)
Abstract IA015: Immunoprevention of triple negative breast cancer by TOP2A derived peptide vaccination (2022) (0)
Abstract 1050: Lapatinib suppresses RTK-mediated signaling through multiple signaling pathways in the chemically-induced ER+ model of mammary cancer (2011) (0)
Use of a carcinogen-induced rat mammary tumor model both to identify chemopreventive agents and to examine potential efficacy biomarkers (2007) (0)
PROGRESS IN CANCER CHEMOPREVENTION Inhibit Carcinogen Uptake Inhibit Carcinogen Formation Deactivate Carcinogen Restore Normal Cell Growth / Differentiation Modulate Signal Transduction Pathways Inhibit Poh / amine Metabolism Inhibit Arachidonic (2006) (0)
Abstract 4678: Unexpected lack of activity of Bardoxolone (5MeCDDO) in progression period of rodent models of breast, intestinal and head and neck cancers. What does it mean for the ARE as a primary prevention target. (2013) (0)
Abstract A106: Efficacy of EGFr inhibitors gefitinib on development of OH-BBN-induced rat bladder tumors: Dose dependency and modulation of biomarkers (2010) (0)
Abstract P1-08-04: Doses of Selective Estrogen Receptor Modulations (SERMS) Required for Prevention and Therapy of Chemically-Induced Mammary Cancers (2010) (0)
Effect of bexarotene and mushroom extract lsy16 on intestinal neoplasia in the Apc Min/+ mouse model (2006) (0)
Early biomarkers of response of mammary tumors to preventive/therapeutic agents (2006) (0)
Abstract 440: Potentiation of EGFR peptide cancer vaccine by an orally bioavailable glutamine antagonist prodrug JHU-083 (2021) (0)
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma (2018) (0)
Abstract 4873: Genistein and soy isoflavone isolate decreased tumor incidence and multiplicity in a Sprague-Dawley ER-positive breast cancer model. (2013) (0)
Perillyl alcohol has a chemopreventive effect on 4- -1- -1-butanone induced tumorigenesis in C3A F-1 mouse lung (1997) (0)
Vol. 35, 1999 (1999) (0)
Abstract A92: Chemoprevention of small cell lung carcinomas in mice by the retinoid X receptor agonist bexarotene (2009) (0)
Abstract 3700: Proteomic credentialing in a model for chemoprevention studies of urinary bladder cancer (2011) (0)
226 Efficacy of cancer preventing drugs administered by intermittent dosing regimens (2014) (0)
Abstract 962: Similar preventive effects of naproxen and NO-naproxen in a chemically-induced model of urinary bladder cancer: Dose dependency, gene expression and toxicity (2010) (0)
Abstract 188: Preventive effect of aerosolized bexarotene in three major subtypes of lung cancer: adenocarcinoma, squamous cell carcinoma and small cell lung cancer in mice (2017) (0)
222 Estimating predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal tumor assays (2014) (0)
Abstract 4780: Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures (2012) (0)
Chemical enhancement of simian adenovirus SA7 oncogenic transformation of Syrian golden hamster embryo (SHE) cells (1986) (0)
Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations (2023) (0)
Abstract 808: Chemoprevention of colon cancer by DFMO, sulindac and NO-sulindac administered individually or in combinations in male F344 rats (2011) (0)
A gene expression signature predicts chemopreventive response of an EGFR inhibitor in a rat mammary cancer model. (2009) (0)
Abstract C45: Preventive effect of Iressa in the hydroxybutyl(butyl) nitrosamine (OH‐BBN) induced model of bladder cancer: Dose dependency, treatment timing, and alterations in biomarkers (2009) (0)
Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers (2019) (0)
Subject Index Vol. 35, 1999 (1999) (0)
Preventing the Development of Breast Cancer by Immunizing with Multi-Antigen Vaccines Targeting Proteins Associated with Oncogenesis. (2009) (0)
Abstract 2423: Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents (2017) (0)
Abstract 4584: A novel combination of a multipeptide KRAS vaccine and an ACAT1 inhibitor to prevent lung cancer (2020) (0)
Molecular and Cellular Pathobiology Identi fi cation of an Aurora Kinase Inhibitor Speci fi c for the Aurora B Isoform (2013) (0)
Carcinogenic Process Cancer Depends on Time of Administration during Chemopreventive Efficacy of Sulindac Sulfone against Colon (2013) (0)
Clinical development plan: DHEA analog 8354 (1994) (0)
Abstract 182: Differential response of epithelial cells from colorectal adenomas and adjacent nonneoplastic colonic mucosa to aspirin and atorvastatin in Apc+/Min-FCCCmice. (2013) (0)
The new coxib drug R-109339 is a very effective chemopreventive agent for decreasing adenoma multiplicity (2003) (0)
Abstract 4664: Fast analysis and quantification of collagen fibril alignment in the tumor microenvironment in an MNU-induced model of mammary carcinogenesis (2010) (0)
Abstract A84: Lack of efficacy of the anti-diabetic drug metformin in the ER+ methylnitrosourea (MNU)-induced and the ER− MMTV-Neu/p53KO models of mammary cancer. (2011) (0)
Chemotherapeutic Agents Taxol or Adriamycin-Inositol and myo Agents Green Tea or Dexamethasone / ChemopreventiveTumorigenesis : p 53-independent Efficacy of Mutation Accelerates Pulmonary p 53 A GermLine Updated (2000) (0)
Abstract A93: Lapatinib suppresses RTK-mediated signaling through multiple signaling pathways in the chemically induced ER+ model of mammary cancer (2010) (0)
Abstract 837: Reproducibility of efficacy results for chemopreventive agents in the methylnitrosourea-induced rat mammary cancer model (2016) (0)
Abstract 2681: Identification of potential immunologic targets found in mice and man that are expressed in colon adenomas and colorectal cancer (2011) (0)
Abstract 5695: Nitric oxide-donating naproxen inhibits β-catenin-mediated TCF signaling in colorectal cancer cells more effectively than naproxen (2010) (0)
Abstract 960: Use of MMTV-Neu/P53 KO transgenic mice to screen for potential chemopreventive agents (2010) (0)
Abstract SY24-03: Vaccines for the prevention of cancer (2011) (0)
Preventive effects of the RXR agonists targretin and UAB-30 in transgenic mouse models of estrogen receptor (ER) negative mammary cancer (2007) (0)
Tumor promoting effects of the PPAR gamma agonist rosiglitazone during the progression stages of OH-BBN induced urinary bladder cancer (2007) (0)
Abstract 647: Immunoprevention of triple negative breast cancer by a TOP2A multi-peptide vaccine (2019) (0)
Abstract PR09: Intermittent dosing regimens maintain efficacy of several cancer preventing drugs (2015) (0)
Abstract P3-11-04: Metabolic profiles in female Sprague-Dawley rats receiving either a standard (4% fat) or Western (20% fat) diet and changes in rats bearing mammary cancers (2016) (0)
Abstract 1252: 6-c-(e-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1 (2014) (0)
P3-11-07: Mammary Gland Biopsy To Examine Surrogate Endpoint Biomarkers of Preventive Agent Efficacy. (2011) (0)
Effects of Pioglitazone on Chemically Ther ced Lung Carcinogenesis in Mice (2010) (0)
Abstract A82: Bardoxolone (5MeCDDO), which induces the antioxidant response element (ARE), is ineffective in inhibiting cancer progression but inhibits cancer initiation in rodent models of cancer. What does it mean for the ARE as a primary prevention target? (2011) (0)
Abstract 441: Degree or extent of radially-aligned collagen fibrils in the tumor-stromal interface of rodent mammary tumor tissue is an indicator of chemotherapeutic potential of the EGFr inhibitor, Gefitinib (2011) (0)
Prevention of hydroxybutyl(butyl)nitrosamine(OH-BBN)-induced urinary bladder cancer in Fischer-344 rats by cyclooxygenase and lipoxygenase inhibitors. (2006) (0)
H response to treatment with the anticarcinogen 3 Identification of novel transcriptional networks in (2016) (0)
Abstract 1190: Differences in responsiveness of drug-sensitive and drug-resistant human bladder cancer cells to specific EGFR inhibitors (2010) (0)
Abstract 3698: Chemopreventive efficacy of pioglitazone on lung cancer in mice (2011) (0)
Comparative chemopreventive efficacy of Naproxen and NO-Naproxen in rodent models of colon and bladder cancer. (2008) (0)
Abstract 824: Effects of metfornin on mammary carcinogenesis and metabolic profiles in methylnitrosourea-treated rats on standard or Western diets (2016) (0)
Surrogate endpoint biomarker (SEB) guided drug development: A practical strategy for chemoprevention(CP) of preinvasive cancer (PRECA) (1997) (0)
Abstract A33: Identification of potential immunologic targets in mice and man that are overexpressed in colon adenomas and colorectal cancer (2010) (0)
Abstract 896: Correlation between modulation of RNA expression and the preventive and therapeutic efficacy of Tamoxifen in an ER+ model of breast cancer (2015) (0)
Abstract 2292: Absent E2 liganded AhR inhibits tumor inhibition by ERα in Min mice (2011) (0)
TAMOXIFEN CITRATE + BEXAROTENE IN FEMALE RATS 2 3 (2007) (0)
Identification of urinary biomarkers to distinguish tumor bearing and control rats in the methylnitrosourea (MNU) – induced model of mammary carcinogenesis: use of label-free, comparative, ultra-high resolution nano-LC mass spectrometry. (2009) (0)
Differential Gene Expression in Human Lung Adenocarcinomas and Squamous Cell Carcinomas 1 (2002) (0)
Abstract 5246: Effects of bazedoxifene either alone or in combination with letrozole in the prevention of chemically induced mammary cancers (2017) (0)
The metabolism of dibenz(a,h)anthracene (dba) by mouse hepatic microcomses and its relationship to dba-induced tumor formation. Abstr. (1982) (0)
Abstract P2-07-03: Tumors Resistant to Iressa Treatment Show Increased Aberrant Expression of CREB (Ser133) (2010) (0)
Abstract B48: Lack of efficacy of the anti-diabetic drug metformin in the ER+ methylnitrosourea (MNU)-induced and the ER- MMTV-Neu/p53KO models of mammary cancer (2010) (0)
Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA (2021) (0)
Abstract 4777: Computational strategies for finding protein targets of flavonoids (2012) (0)
Abstract 2626: Metabolic profiles and potential pharmacodynamic biomarkers in female Sprague-Dawley rats on a standard (4% fat) or Western (20% fat) diet and treated with known active or inactive chemopreventive agents (2016) (0)
Abstract 818: Modulation of gene expression and cell cycle signaling pathways in Iressa-treated urinary bladder cancer in rats (2011) (0)
Abstract C220: Characterization of potential immunologic targets found in both mice and man that are expressed in colon adenomas and colorectal cancer. (2011) (0)
An integrated platform for the discovery and confirmation of protein urinary biomarkers for bladder cancer in a carcinogen induced rat model. (2008) (0)
Influence of W-Methyl-W-Nitrosourea, Testosterone, and A^-(4-Hydroxyphenyl)-all- Â¿ra/is-retinamide on Prostate Cancer Induction in Wistar-Unilever Rats1 (2006) (0)
225 Molecular targets of interest to the NCI PREVENT cancer preclinical drug development program (2014) (0)
Abstract A101: Dose-related suppression of rat oral carcinogenesis by the EGF receptor-tyrosine kinase inhibitor, gefitinib (2010) (0)
Abstract A42: Doses of selective estrogen receptor modulations (SERMS) required for prevention and therapy of chemically induced mammary cancers (2010) (0)
Abstract 854: Alternative dosing regimens with the EGFr inhibitors (Gefitinib and Lapatinib) in a mammary cancer model: Prevention efficacy (2011) (0)
Abstract 2809: Chemopreventive studies of multiple agents in the methylnitrosourea-induced ER+mammary cancer model in animals on standard and Western diets (2015) (0)
Abstract B48: Animal models in use by the NCI PREVENT Cancer Preclinical Drug Development Program (2018) (0)
Abstract 1618: Inhibition of lung tumorigenesis by a novel small molecule CA170 targeting the immune checkpoint protein VISTA (2021) (0)
Abstract P5-11-01: Correlation of the effects of potential and known chemopreventive agents on proliferation rates in normal mammary glands and mammary cancers with their chemopreventive efficacy (2015) (0)
Abstract B51: Prevention of mouse lung tumors by combinations containing SAHA and atorvastin (2010) (0)
Abstract 1698: Immunoprevention of KRAS-driven lung adenocarcinoma by a multi-peptide KRAS vaccine (2017) (0)
Modulation of Gene Expression and Cell-Cycle Signaling Pathways by the EGFR Inhibitor Ge fi tinib ( Iressa ) in Rat Urinary Bladder Cancer (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ronald A. Lubet?

Ronald A. Lubet is affiliated with the following schools:

Ronald A. Lubet's Academic­Influence.com Rankings

Why Is Ronald A. Lubet Influential?

Ronald A. Lubet's Published Works

Published Works

What Schools Are Affiliated With Ronald A. Lubet?

Ronald A. Lubet's AcademicInfluence.com Rankings